Growth factor
AssigneeUniversity of Bradford
InventorsJason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Atkinson, Mike Bibby
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
Claims27
A compound, or pharmaceutically acceptable salt thereof, comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site.
3-21. (canceled)
(canceled)
(canceled)
(canceled)
A compound, or pharmaceutically acceptable salt thereof, of formula (VII)
- X-Y-Z (VII)
- wherein X;
- is a vascular disrupting agent (VDA);
- Y is a matrix metalloproteinase (MMP) proteolytic cleavage site;
- and
- Z is an anti-cancer agent.
31-33. (canceled)
Use of a MMP proteolytic cleavage site in the site specific activation of a VDA.
(canceled)
(canceled)
Dependencies are inferred from the claim text.